Patent SG-11201806966S-A (SG)
Title: Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt
Inventor: KIM AERI
IPC: C07D207/48
Filed: 2017-03-17
Abstract: WO 17 / 16 457 6 A8 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11111111111111111111111111111111111 0M 011 100 IIHOO #10# (10) International Publication Number WO 2017/164576 A8 28 September 2017 (28.09.2017) WI PO I PCT (51) International Patent Classification: C07D 207/48 (2006.01) A61K 31/40 (2006.01) (21) International Application Number: PCT/KR2017/002914 (22) International Filing Date: 17 March 2017 (17.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10-2016-0036080 25 March 2016 (25.03.2016) KR (71) Applicant: DAEWOONG PHARMACEUTICAL CO., LTD. [KR/KR]; 35-14, Jeyakgongdan 4-gil, Hyang- nam-eup, Hwaseong-si, Gyenoggi-do 18623 (KR). (72) Inventors: KIM, Aeri; 109-1701, 154, Yeongjung-ro, Yeongdeungpo-gu, Seoul, 07226 (KR). CHO, Kwan Hyung; 111-1902, 156, Hwamyeongsindosi-ro, Buk-gu, Busan, 46525 (KR). (74) Agent: YOU ME PATENT AND LAW FIRM; 115 Teheran-ro, Gangnam-gu, Seoul 06134 (KR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, (54) Title: NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4- METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT FIG. 1 2-Theta (57) : The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5- (2,4- difluorophenyl)- 1 ((3-fluorophenyl)sulfony1)-4-methoxy-1H-pyrrol-3-y1)-N- methylmetlianamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used. [Continued on next page] WO 2017/164576 A8 MIDEDIMOMOIDEIROIDEMOMMINIVINEROMEME# SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (48) Date of publication of this corrected version: 09 August 2018 (09.08.2018) (15) Information about Correction: see Notice of 09 August 2018 (09.08.2018)